Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. [electronic resource]
Producer: 20170104Description: e5128 p. digitalISSN:- 1414-431X
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bortezomib -- adverse effects
- Diarrhea -- chemically induced
- Female
- Humans
- Immunosuppressive Agents -- adverse effects
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Neutropenia -- chemically induced
- Peripheral Nervous System Diseases -- chemically induced
- Pharmacovigilance
- Prospective Studies
- Risk Factors
- Thalidomide -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Observational Study
There are no comments on this title.
Log in to your account to post a comment.